matthew mackey

Project team leadership and pre-clinical drug development in autoimmunity, atopy, and cancer immunotherapy.

Responsible for providing organizational strategy and scientific oversight on ImmuNext programs focused on the negative immune checkpoint regulator molecule termed VISTA (“V-domain Ig suppressor of T cell activation”). Key programs include: - VISTA-Ig, an immuno-modulatory agonist for autoimmune disease treatment - Anti-VISTA, a negative checkpoint regulator antagonist for cancer immunotherapy http://immunext.com/

Laboratory of Dr. Ronald N. Germain. Research Summary: developed novel retroviral technologies to enable genetic manipulation of primary immunocytes and applied technology for structure-function studies of the CD40 costimulatory pathway in dendritic cells.

This site is intended only for residents of the United States and its territories. Merck is known as MSD outside the United States and Canada. Today's Merck is a global healthcare leader working to help the world be well. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. Merck. Be well. For more information, visit www.merck.com.

Laboratory of Dr. Randolph J. Noelle; Department of Microbiology & Immunology. Thesis Summary: characterized the role of CD40/CD40Ligand (CD154) costimulation in the generation of protective tumor immunity following cancer vaccination in mice, with focus on the role of CD40 in dendritic cell function and T-cell priming.